TABLE 1.

Study design^a

Cohort no.	Study drug-dose	Infusion time—frequency	Participants
Cohort 1	WCK 6777 2 g (ERT 1 g + ZID 1 g) or placebo	30 (±5) min—once daily for 7 days	8 (6 drug combination, 2 placebo)
Cohort 2	ERT 2 g or placebo	60 (±10) min—once daily for 7 days	8 (6 drug, 2 placebo)
Cohort 3	ZID 2 g	60 (±10) min—once daily for 7 days	6 (all drug)
Cohort 4	WCK 6777 4 g (ERT 2 g + ZID 2 g) or placebo	60 (±10) min—once daily for 7 days	8 (6 drug combination, 2 placebo)
Cohort 5	ERT 3 g or placebo	120 (±10) min—once daily for 7 days	8 (6 drug, 2 placebo)
Cohort 6	ZID 3 g	120 (±10) min—once daily for 7 days	6 (all drug)
Cohort 7	WCK 6777 6 g (ERT 3 g + ZID 3 g) or placebo	120 (±10) min—once daily for 7 days	8 (6 drug combination, 2 placebo)

^a ERT, ertapenem; ZID, zidebactam. WCK 6777 consists of ertapenem co-administered with zidebactam.